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Introduction: Metformin use has recently been observed to decrease both the rate and mortality of breast cancer.
Our study was aim to determine whether metformin use is associated with survival in diabetic breast cancer
patients by breast cancer subtype and systemic treatment.
Methods: Data from the Asan Medical Center Breast Cancer Database from 1997 to 2007 were analyzed. The study
cohort comprised 6,967 nondiabetic patients, 202 diabetic patients treated with metformin, and 184 diabetic
patients that did not receive metformin. Patients who were divided into three groups by diabetes status and
metformin use were also divided into four subgroups by hormone receptor and HER2-neu status.
Results: In Kaplan-Meier analysis, the metformin group had a significantly better overall and cancer specific survival
outcome compared with non metformin diabetic group (P <0.005 for both). There was no difference in survival
between the nondiabetic and metformin groups. In multivariate analysis, Compared with metformin group, patients
who did not receive metformin tended to have a higher risk of metastasis with HR 5.37 (95 % CI, 1.88 to 15.28) and
breast cancer death with HR 6.51 (95 % CI, 1.88 to 15.28) on the hormone receptor-positive and HER2-negative
breast cancer. The significant survival benefit of metformin observed in diabetic patients who received chemotherapy
and endocrine therapy (HR for disease free survival 2.14; 95 % CI 1.14 to 4.04) was not seen in diabetic patients who
did not receive these treatments.
Conclusion: Patients receiving metformin treatment when breast cancer diagnosis show a better prognosis only if
they have hormone receptor-positive, HER2-positive tumors. Metformin treatment might provide a survival benefit
when added to systemic therapy in diabetic patients.Introduction
Diabetes has been found to be a risk factor for breast
cancer in some studies, and patients with diabetes may
have poorer outcomes than nondiabetic patients [1– 3].
A recent British cohort study found that women with
breast cancer and pre-existing diabetes had a 49 % (95 %
CI, 1.17 to 1.88) increased all-cause mortality risk com-
pared with women with breast cancer but without dia-
betes [4]. Obesity is associated with type 2 diabetes and
is itself a risk factor for breast cancer and possibly for a* Correspondence: ahnsh@amc.seoul.kr
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tor linking diabetes, obesity, and metabolic syndrome to
cancer may be insulin resistance and the consequent
hyperinsulinemia associated with these conditions [6].
Metformin is widely used in the treatment of type 2
diabetes mellitus to increase insulin sensitivity and im-
prove glycemic control [7, 8]. In addition, numerous ex-
perimental, epidemiologic, observational, and clinical
studies have shown that metformin has antitumor effects
[9, 10]. In particular, metformin treatment has been
associated with lower breast cancer incidence among
patients with diabetes and higher pathologic complete
response in patients with early-stage breast cancer who
were receiving neoadjuvant therapy [11]. Metformin
could decrease breast cancer cell growth either indirectlyle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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factor (IGF) or directly via activation of adenosine
monophosphate-activated protein kinase (AMPK) [12].
Initiation of an AMPK-dependent energy stress re-
sponse, resulting in inhibition of the mammalian target
of rapamycin (mTOR) signaling pathway, leads to re-
duced protein synthesis and proliferation of cancer cells
[13]. Thus, the anticancer effects of metformin are medi-
ated through a systemic improvement in the metabolic
profile and by directly targeting tumor cells [10]. How-
ever, results from observation studies on survival benefit
in breast cancer patients with diabetes are conflicting. A
recent study failed to show a significant reduction in
breast cancer mortality in patients treated with metfor-
min [14] but some fairly small studies have reported a
beneficial effect of metformin use on survival in patients
with human epidermal growth factor receptor-2 (HER2)-
positive tumors [15].
Based on the evidence reviewed above, a growing
number of clinical intervention studies of metformin
have been initiated [16]. A phase III trial of adjuvant
metformin has been initiated in women with breast
cancer (NCIC CTC MA.32) [9] and a phase II trial of a
neoadjuvant setting for postmenopausal breast cancer
patients (METEOR study) has also started patient en-
rolment [10]. However, the accrual and treatment
process is still ongoing, and several years of follow up
are needed to determine if there is any survival benefit.
In addition, little is known about the effects of metfor-
min on different subtypes of breast cancer. In our
current study, we explored the association between
metformin use and survival outcomes in diabetic and
nondiabetic breast cancer patients and analyzed benefit
according to breast cancer subtype using immunohisto-
chemical staining.
Methods
This study was approved by the institutional review
board of Asan medical center and conducted in accord-
ance with the Helsinki declaration. No consent was
needed for this retrospective analysis using a web-based
database without personal information.
Patients
Data from the Asan Medical Center Breast Cancer Data-
base (AMCBCD) from 1997 to 2007 were analyzed. A
total of 6,967 patients who were diagnosed with breast
cancer and underwent surgery were included in this
study. Patients were categorized by diabetes status and
metformin use. They are not preselected on these expo-
sures. Patients with a database diagnostic code (ICD-9,
250) during their outpatient clinic visits or a hospital ad-
mission were assigned to the diabetic group. For the dia-
betic patients, whether or not they received metforminas an antidiabetic drug on diagnosis of breast cancer was
the criterion for dividing the groups into metformin or
non-metformin users.
AMCBCD provides detailed clinicopathologic infor-
mation on breast cancer. Eight surgical oncologists who
specialized in breast cancer reviewed all available sur-
vival data for this study. Patient age (<50 years versus
≥50 years), body mass index (BMI), tumor size, lymph
node involvement, hormone receptor and HER2-neu sta-
tus, and adjuvant treatment status were recorded. Sur-
vival data, which included disease-free survival (DFS),
cancer-specific survival (CSS) and overall survival (OS)
were included in this cohort, and for the survival data,
eight breast cancer specialists checked the survival data
using patients’ records. Positive staining for estrogen re-
ceptor (ER) or progesterone receptor (PR) was defined
as a score of more than 3+ and HER2 positivity was
defined as a score of 3+ by immunohistochemical
(IHC) staining or HER2 gene amplification by fluores-
cence in situ hybridization. The hormone receptor-
positive group comprised ER-positive and/or PR-positive
patients. Hormone therapy included adjuvant tamoxifen,
ovarian suppression or ablation with endocrine therapy,
and aromatase inhibitors. Until 2007, the anti-HER2
therapy (Trastuzumab) was not covered by Korean
government health insurance. Few people had received
anti-HER2 treatment among the patients who had HER2/
neu-overexpressing breast cancer. The patients who had
received anti-HER2 treatment were excluded from this
study. Patients were divided into three groups by diabetes
status and metformin use: a nondiabetic group, a metfor-
min group (diabetic patients who received metformin),
and a non-metformin group (diabetic patients who did
not receive metformin after diagnosis of breast cancer).
Moreover, patients were also divided into four subgroups
by hormone receptor and HER2-neu status: hormone
receptor-positive and HER2-negative, hormone receptor-
positive and HER2-positive, hormone receptor-negative
and HER2-positive, and hormone receptor-negative and
HER2-negative.
Statistical analysis
The demographic and clinical characteristics of the three
study groups were analyzed with the chi-square test and
the differences among groups were compared with one-
way analysis of variance (ANOVA) and post hoc Scheffé
test. The primary endpoint was DFS. Events used for the
analysis of the end point of disease-free survival included
local, regional, and contralateral breast cancer or distant
breast cancer recurrence. Curves for DFS (until date of
recurrence or death), CSS (until date of death from
breast cancer), OS (until date of death) were calculated
with the Kaplan-Meier product-limit method. Differ-
ences between groups were analyzed with the log-rank
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size, lymph node metastasis, ER status, PR status, HER2-
neu status, chemotherapy and hormone therapy) to
disease-free survival, cancer-specific survival and OS
were analyzed with multivariate Cox regression analysis.
For subgroup analysis using IHC (Fig. 1, Table 1) and
systemic treatment (Fig. 2), chemotherapy and hormonal
therapy treatment were not considered for multivariate
analysis. On multivariate analysis, the metformin group
was regarded as a reference for calculating the hazard
ratio (HR). To exclude a biased result, sensitivity analysis
was conducted to check the consistency of the HR
according to each clinically important prognostic factor
for breast cancer recurrence (Fig. 3). All other statistical
analyses were carried out with SPSS software (version
18.0; SPSS, Chicago, IL, USA), with a P-value ≤0.05
considered statistically significant.Fig. 1 Disease-free survival according to diabetes mellitus and metformin trea
staining of estrogen receptor (ER), progesterone receptor (PR) and human epi
HER2-negative. (b) Hormone receptor-positive, HER2-positive. (c) Hormone re
HER2-negative Adjusted for tumor size (≤2 versus > 2 cm), lymph node status
(non-amplification versus amplification). HR, hazard ratio; MET, metformin; DMResults
Patient demographic and clinical characteristics
This study cohort comprised 6,581 nondiabetic patients,
202 diabetic patients receiving metformin, and 184 dia-
betic patients not receiving metformin. The demo-
graphic and clinical characteristics of the study patients
are summarized in Table 1. Patients in the diabetic
groups were older than those in the nondiabetic group
(P <0.001), and the mean BMI levels were higher in the
diabetic patient group (P <0.001). Patients with diabetes
mellitus were also less likely to have received adjuvant
chemotherapy than nondiabetic patients (P <0.001);
however, there were no differences between the metfor-
min and non-metformin groups (P = 0.155, by one-way
ANOVA with post hoc Scheffé test). Tumor size, lymph
node metastasis, ER and PR status, HER2-neu status, the
percentages of patients receiving adjuvant hormonetment among different intrinsic subtypes using immunohistochemical
dermal growth factor receptor-2 (HER2). (a) Hormone receptor-positive,
ceptor-negative, HER2- positive. (d) Hormone receptor-negative,
(positive versus negative), ER status, PR status, and HER2-neu status
, diabetes mellitus
Table 1 Patient demographics and clinical characteristics by study group
Metformin Non metformin Non diabetic P-value
(n = 202) (n = 184) (n = 6,581)
Number % Number % Number %
Age at operation, years
Median (range) 55(10.5) 59(10.2) 46(9.6) <0.001
<50 68 33.7 40 21.7 4370 66.4
≥50 134 66.3 144 78.3 2211 33.6
Body mass index, kg/m2
<18.5 0 0 4 2.2 242 3.7 <0.001
≥18.5, <25 84 41.6 75 40.8 4644 70.8
≥25 118 58.4 105 57.1 1669 25.5
Serum glucose, mg/dL
Median 165.5 150.5
≤150 83 40.7 93 50 0.068
>150 121 59.3 93 50
HbA1C, %
<7 51 32.1 29 35.8 0.566
≥0.5108 67.9 52 64.2
Tumor size, cm
≤2 100 49.5 93 50.5 3535 53.7 0.356
>2 102 50.5 91 49.5 3046 46.3
Node metastasis
No 110 54.5 110 59.8 3860 58.7 0.463
Yes 92 45.5 74 40.2 2721 41.3
Chemotherapy
No 66 32.7 80 43.5 1799 27.3 <0.001
Yes 136 67.3 104 56.5 4782 72.7
Endocrine therapy
No 58 28.7 54 29.3 2013 30.6 0.801
Yes 144 71.3 130 70.7 4568 69.4
Subgroup according to IHC using ER, PR and HER2
Hormone receptor+, HER2- 107 53.0 98 53.3 3390 51.5 0.385
Hormone receptor+, HER2- 27 13.4 18 9.8 916 13.9
Hormone receptor-, HER2+ 35 17.3 25 13.6 928 14.1
Hormone receptor-, HER2- 33 16.3 43 23.4 1347 20.5
HER2, human epidermal growth factor receptor-2; ER, estrogen receptor; PR, progesterone receptor; HbA1c, hemoglobin A1C
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PR, and HER2-neu status analyzed by IHC were not sig-
nificantly different among the three groups.
Breast cancer survival according to diabetes mellitus and
metformin treatment
The median follow-up period was 100.3 months. In
Kaplan-Meier analysis, the metformin group had sig-
nificantly increased OS and cancer-specific survival com-
pared with diabetic patients who did not receive metformintherapy (log-rank test, both P <0.005) (Fig. 4a, b). There
were 1,262 recurrences (18.1 %): 42 (20.8 %) in the
metformin group, 52 (28.3 %) in the non-metformin
group and 1,168 (17.7 %) in the nondiabetic group.
Patients in the metformin group experienced better DFS
than diabetic patients in the non-metformin group,
which was borderline statistically significant (log-rank
test, P = 0.058; Fig. 4c) and there was no difference from
the nondiabetic group. On univariate analysis, the HR for
DFS in the non-metformin group compared with the
Fig. 2 (See legend on next page.)
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Fig. 2 Disease-free survival according to systemic treatment of breast cancer among nondiabetic patients, diabetic patients receiving metformin,
and diabetic patients not receiving metformin. (a) Patients who received chemotherapy. (b). Patients who did not receive chemotherapy.
(c) Patients who received endocrine therapy. (d) Patients who did not received endocrine therapy. (e) Patients who did not receive any
treatment. (f) Patients who received only chemotherapy. (g) Patients who received endocrine therapy only. (h) Patients who received
chemotherapy and endocrine therapy. Adjusted for tumor size (≤2 versus > 2 cm), lymph node status (positive versus negative), estrogen
receptor status, progesterone receptor status, and human epidermal growth factor receptor-2 (HER2)-neu. status (non-amplification versus
amplification). HR, hazard ratio; MET, metformin; DM, diabetes mellitus
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(95 % CI, 1.07 to 2.68) for CSS (Table 2). After
adjusting for age, BMI, tumor size, lymph node metastasis,
ER, PR, and HER2-neu status, and systemic treatment,
patients who did not receive treatment with metformin
tended to have shorter OS (HR 1.87; 95 % CI 1.25 to 2.81),
CSS (HR 1.85; 95 % CI 1.17 to 2.92) and DFS (HR 1.59;
95 % CI 1.06 to 2.39) than those of the metformin
group (Fig. 4, Table 3).
Subgroup analyses according to intrinsic subtype using
immunohistochemical staining of ER, PR, and HER2
The Kaplan-Meier estimates of DFS stratified by the four
subgroups are shown in Fig. 1. Hormone receptor-Fig. 3 Recurrence risk of breast cancer according to each prognostic facto
receptor-2 (HER2)-negative. (b) Hormone receptor-positive, HER2-positive. (c)
negative, HER2-negativepositive and HER2-positive patients showed a DFS bene-
fit (log-rank test, P = 0.001; Fig. 1b) in those patients
who received metformin compared with the diabetic
non-metformin group, but the other subgroups
showed no significant differences (Fig. 1a, c, d). Multivari-
ate Cox proportional hazards regression analysis of
the DFS of diabetic patients with hormone receptor-
positive and HER2-positive breast cancer was carried out
with a model consisting of the categorical covariates, age
(<50 years versus ≥50 years), BMI (<25 kg/m2 versus ≥25
kg/m2), tumor size (T1 versus T2, 3, or 4), and node me-
tastasis, using the metformin group as the reference.
There were significant differences with regard to the risk
of disease recurrence (HR 5.37; 95 % CI 1.88 to 15.28) andr. (a) Hormone receptor-positive, human epidermal growth factor
Hormone receptor-negative, HER2-positive. (d) Hormone receptor-
Table 2 Univariate Cox proportional hazards model for disease-free survival and cancer-specific survival
Disease-free survival Cancer-specific survival
P-value Hazard ratio 95 % CI P-value Hazard ratio 95 % CI
Metformin
Metformin 1 1
Non-metformin versus metformin 0.05 1.50 1.0 to 2.25 0.02 1.69 1.07 to 2.68
Non-DM versus metformin 0.39 0.87 0.64 to 1.19 0.29 0.83 0.58 to 1.18
Age, years
≤50 0.652 0.97 0.87 to 1.09 0.023 0.83 0.73 to 0.96
BMI, kg/m2
High 1 1
Low versus high 0.141 1.24 0.94 to 1.64 0.362 1.17 0.84 to 1.64
Normal versus high 0.132 0.91 0.80 to 1.03 0.064 0.87 0.75 to 1.01
Tumor size, cm
T ≥2 <0.001 2.59 2.30 to 2.91 <0.001 3.10 2.68 to 3.59
Node metastasis
Node-positive <0.001 2.79 0.49 to 3.13 <0.001 3.58 3.10 to 4.13
Estrogen receptor status
Positive 0.026 0.78 0.63 to 0.97 <0.001 1.85 1.62 to 2.11
Progesterone receptor status
Positive 0.001 0.72 0.60 to 0.87 <0.001 1.93 1.69 to 2.21
HER2 status
Positive <0.001 1.44 1.28 to 1.62 <0.001 1.56 1.37 to 1.79
Chemotherapy
Yes 0.098 0.82 0.65 to 1.04 <0.001 0.38 0.31 to 0.46
Endocrine therapy
Yes 0.108 0.83 0.67 to 1.04 <0.001 1.78 1.56 to 2.03
HER2, human epidermal growth factor receptor-2; DM, diabetes mellitus
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metformin and metformin groups, but there were no dif-
ferences between the nondiabetic and metformin groups
(Fig. 1b, Table 4).
Subgroup analyses according to systemic treatment of
breast cancer among nondiabetic patients, diabetic
patients receiving metformin, and diabetic patients not
receiving metformin
For patients who did not receive chemotherapy and/or
endocrine therapy, there were no statistically signifi-
cant differences in DFS among the nondiabetic, non-
metformin, and metformin groups. (Fig. 2a, c, e). Among
the patients who had received endocrine therapy only or
chemotherapy only, the metformin treatment group did
not differ in DFS compared with the non-metformin treat-
ment group (Fig. 2f, g). Among the patients who received
chemotherapy and endocrine therapy, the non-metformin
diabetic group had decreased DFS (HR 2.14; 95 % CI 1.14
to 4.04) compared with the metformin group, afteradjusting for age, BMI, tumor size, lymph node metastasis,
ER, PR and HER2.
Discussion
The results of this study confirmed that treatment with
metformin after breast cancer diagnosis in diabetic pa-
tients improves DFS and reduces mortality. The most
important finding was that the survival difference ac-
cording to metformin treatment and diabetes was only
observed on IHC staining in patients with hormone
receptor-positive and HER2-positive tumors. The sur-
vival benefit was clear for patients who received chemo-
therapy or endocrine therapy compared with those who
did not receive either of those treatments. These find-
ings are consistent with several other recent analyses in-
volving large numbers of subjects. To our knowledge,
our present study is the first to include breast cancer
clinicopathologic information and recurrence for the
analysis of the relationship between metformin and
breast cancer recurrence and mortality. The most
Fig. 4 Breast cancer survival according to diabetes mellitus (DM) and metformin treatment (MET). (a) Overall survival. (b) Cancer-specific survival.
(c) Disease-free survival. Adjusted for tumor size (≤2 versus > 2 cm), lymph node status (positive versus negative), estrogen receptor status, progesterone
receptor status, human epidermal growth factor receptor-2 (HER2)-neu status (non-amplification versus amplification), chemotherapy and endocrine therapy
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Table 3 Multivariate Cox proportional hazards model for disease-free survival and cancer-specific survival
Disease-free survival Cancer-specific survival
P-value Hazard ratio 95 % CI P-value Hazard ratio 95 % CI
Metformin
Metformin 1 1
Non-metformin versus metformin 0.025 1.59 1.06 to 2.39 0.009 1.85 1.17 to 2.92
Non-DM versus metformin 0.483 0.90 0.66 to 1.22 0.519 0.89 0.62 to 1.27
Age, years
≤50 0.584 1.04 0.92 to 1.17 0.106 0.89 0.77 to 1.03
Body mass index, kg/m2
High 1 1
Low versus high 0.009 1.17 1.1 to 1.17 0.018 1.52 1.08 to 2.14
Normal versus high 0.639 1.03 0.91 to 1.17 0.597 1.04 0.90 to 1.21
Tumor size, cm
T ≥2 <0.001 2.03 1.78 to 2.31 <0.001 2.18 1.86 to 2.56
Node metastasis
Node positive <0.001 2.59 2.26 to 2.96 <0.001 3.09 2.63 to 3.64
Estrogen receptor status
Positive 0.009 0.79 0.66 to 0.94 0.026 0.78 0.63 to 0.97
Progesterone receptor status
Positive 0.004 0.80 0.68 to 0.93 0.001 0.72 0.60 to 0.87
HER2 status
Positive <0.001 1.27 1.13 to 1.44 <0.001 1.29 1.12 to 1.49
Chemotherapy
Yes <0.001 0.70 0.58 to 0.84 0.098 0.82 0.65 to 1.04
Endocrine therapy
Yes 0.312 0.91 0.75 to 1.10 0.108 0.83 0.67 to 1.04
HER2, human epidermal growth factor receptor-2; DM, diabestes mellitus
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formation on the breast cancer characteristics, such as
tumor size, lymph node metastasis, hormone receptor
status, HER2 status, and treatment methods. These fac-
tors are the most important determinants of survival
outcome. Hence, without considering the prognostic and
predictive factors of breast cancer, any evaluation of the
prognostic relationship between breast cancer and met-
formin is uncertain. Moreover, most previous studies
have compared OS, and some have compared CSS, but
few reports have explored the DFS in breast cancer and
metformin treatment (Table 5) [12, 14, 15, 17–19].
Metformin is considered a hybrid anticancer compound
that combines both long-lasting effects that involve the
persistent lowering of blood insulin and glucose levels and
the immediate potency of a cancer cell-targeting molecu-
lar agent that concurrently suppresses the pivotal AMPK/
mTOR axis and several protein kinases, including crucial
cancer-related tyrosine kinase receptors [20]. Metformin
reduces circulating insulin levels in nondiabetic patients,which is relevant because higher insulin and C-peptide
levels have been associated with poor outcomes in breast
cancer patients. A window-o-opportunity study of metfor-
min showed that it reduces Ki67 expression in breast can-
cer and increases apoptosis [13].
In our current study cohort, a beneficial effect of met-
formin was only evident in hormone receptor-positive
and HER2-positive diabetic patients. Few studies have
reported an effect of metformin in a specific subtype of
breast cancer. Bayraktar et al. [17] reported that metfor-
min use during adjuvant chemotherapy does not signifi-
cantly impact survival outcomes in diabetic patients
with triple-negative breast cancer. He et al. [15] demon-
strated that metformin use was associated with signifi-
cantly decreased HRs for breast cancer-specific mortality
in diabetic women with HER2-positive breast cancer
(HR 0.47; 95 % CI 0.24 to 0.90; P = 0.023).
The survival benefit of metformin for hormone-
responsive and HER2-positive cancer can be explained
via two mechanisms. First, metformin can decelerate the
Table 4 Multivariate Cox proportional hazards model for disease-free survival by immunohistochemical staining of ER, PR and HER2
Disease-free survival Cancer-specific survival




Non-metformin versus metformin 0.340 1.35 0.73 to 2.47 0.072 1.92 0.94 to 3.90
Non-DM versus metformin 0.484 0.85 0.54 to 1.34 0.64 0.87 0.50 to 1.54
Age, years
≤50 0.369 0.92 0.76 to 1.12 0.012 0.728 0.57 to 0.93
Body mass index, kg/m2
High 1 1
Low versus high 0.034 1.62 1.04 to 2.54 0.009 2.11 1.20 to 3.68
Normal versus high 0.772 0.97 0.80 to 1.18 0.87 0.98 0.76 to 1.26
Tumor stage
T ≥2 <0.001 2.10 1.73 to 2.54 <0.001 2.44 1.88 to 3.16
Node stage




Non-metformin versus metformin 0.002 5.37 1.88 to 15.28 0.001 6.51 2.06 to 20.55
Non-DM versus metformin 0.648 1.23 0.50 to 3.02 0.502 1.41 0.52 to 3.84
Age, years
≤50 0.120 0.79 0.59 to 1.06 0.006 0.623 0.45 to 0.87
Body mass index, kg/m2
High 1 1
Low versus high 0.050 2.15 1.00 to 4.63 0.446 1.50 0.53 to 4.30
Normal versus high 0.053 1.41 1.00 to 1.99 0.085 1.41 0.95 to 2.09
Tumor stage
T ≥2 <0.001 1.81 1.33 to 4.27 0.004 1.72 1.19 to 2.47
Node stage




Non-metformin versus metformin 0.897 1.07 0.39 to 2.95 0.452 0.61 0.16 to 2.24
Non-DM versus metformin 0.310 0.72 0.38 to 1.36 0.156 0.61 0.31 to 1.21
Age, years
≤50 0.310 1.17 0.89 to 1.54 0.385 1.15 0.84 to 1.57
Body mass index, kg/m2
High 1 1
Low versus high 0.06 1.81 0.98 to 3.35 0.189 1.63 0.79 to 3.38
Normal versus high 0.615 0.93 0.68 to 1.25 0.471 0.88 0.63 to 1.24
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Table 4 Multivariate Cox proportional hazards model for disease-free survival by immunohistochemical staining of ER, PR and HER2
(Continued)
Tumor stage
T ≥2 <0.001 1.98 1.45 to 2.71 <0.001 2.39 1.63 to 3.51
Node stage




Non-metformin versus metformin 0.311 1.62 0.64 to 4.12 0.329 1.66 0.60 to 4.56
Non-DM versus metformin 0.89 1.05 0.50 to 2.24 0.867 1.07 0.47 to 2.42
Age, years
≤50 0.350 1.13 0.88 to 1.44 0.989 1.00 0.76 to 1.32
Body mass index, kg/m2
High 1 1
Low versus high 0.993 1.00 0.54 to 1.83 0.629 1.17 0.62 to 2.23
Normal versus high 0.750 1.04 0.81 to 1.34 0.583 1.08 0.82 to 1.43
Tumor stage, cm
T ≥2 <0.001 1.62 1.26 to 2.08 <0.001 1.76 1.32 to 2.34
Node stage
Node-positive <0.001 2.25 1.78 to 2.84 <0.001 2.45 1.88 to 3.19
HER2, human epidermal growth factor receptor-2. DM, diabetes mellitus
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breast cancer by suppressing the AKT/mTOR signaling
pathway. HER2, insulin receptor, and IGF-I receptor all
act through the same downstream signaling pathway via
PI3K, AKT, and mTOR. Hence, type 2 diabetes mellitus
can further accelerate the growth of HER2-positive breast
cancer given that AKT/mTOR signaling is already active
[15]. Zhu et al. [21] have revealed the development of
metformin-related implications for breast cancer preven-
tion by showing that its systemic administration selectively
targets tumor-initiating cells in a clinically relevant pre-
vention model. Interactions between PI3K/AKT/mTOR
and the estrogen and growth factor signaling and receptor
tyrosine kinase cascade occur at multiple levels to pro-
mote cell proliferation and survival [22, 23]. Therefore,
metformin can show an anticancer effect through sup-
pression of one or more of these signaling pathways,
which is more significant for hormone receptor-positive
and HER2-positive breast cancer.
As a second mechanistic explanation for the survival
benefit of metformin in patients with hormone-responsive
and HER2-positive breast cancer, metformin may increase
the efficacy of systemic treatments for this subtype of tu-
mors by overcoming resistance to these therapies. ER-
positive and HER2-positive tumors are considered to be
an endocrine-resistant subtype of breast cancer. The re-
sistance to antihormonal treatment is due to activation ofthe mTOR pathway [24, 25] and hyperactivation of IGF-I
receptor [26]. Crosstalk between ER and growth factor re-
ceptor pathways has been considered to be a cause for
endocrine therapy resistance in breast cancer [27]. This
resistance mechanism is important in diabetic patients
because the activation of the insulin receptor and IGF-I
receptor signaling pathway is the main mechanism of pro-
moting cancer cell proliferation in patients with diabetes
[28, 29]. The results of the BOLEROII study, which
showed mTOR inhibitor efficacy for hormone-resistant
metastatic breast cancer, have indicated that hyperactiva-
tion of PI3K/AKT/mTOR is the main mechanism of sec-
ondary antihormonal treatment resistance and that the
combined inhibition of ER, HER2, and mTOR is an effect-
ive treatment [30, 31]. Metformin inhibits the PI3K/AKT/
mTOR pathway through IGF receptor inhibition.
Questions remain, however, about the clinical benefits
of metformin as an anticancer agent in patients with
breast cancer. We have shown from our current analyses
that survival differences according to diabetes and met-
formin administration were significant in patients who
received chemotherapy or hormone therapy. This sug-
gests that metformin may have therapeutic efficacy by
cooperatively enhancing the potency of chemotherapy or
hormonal therapy. Our current results are consistent
with findings of previous studies that showed that dia-
betic patients receiving metformin and neoadjuvant
Table 5 Literature reviews of metformin and breast cancer




DFS CSS OS Follow up
(months
or years)





He et al. [15] 2012 Stage II, HER2+ only 88/66/1829 N Y Y 47.6 OS (HR 0.52; 0.28 to 0.97) NA Done
CSS (HR 0.47; 0.24 to 0.90)
Bayraktar et al. [17] 2012 Triple-negative only 63/67/1318 Y Y Y 62 OS (HR 1.22; 0.66 to 2.28) NA Done
RFS (HR 1.37; 0.78 to 2.40)
DMFS (HR 1.63; 0.87 to 3.06)
Peeters et al. [12] 2013 All 508/550/NA N Y Y OS (HR 0.74; 0.58 to 0.96) Increased risk in the
first 12 months after
discontinuation
Done NA
CSS (HR 0.88; 0.59 to 1.29)
Lega et al. [14] 2013 All 1094/1267/NA N Y Y 4.5 (years) OS (HR 0.97; 0.92 to 1.02) Done NA
CSS (HR 0.91; 0.81 to 1.03)
Hou et al. [18] 2013 All 419/594/4612 N N Y 68 OS2 (HR 0.762; 0.6 to 0.986) NA Done
OS3 (HR 1.708; 1.461 to 1.997)
Xiao et al. [19] 2014 Luminal 275/405/5105 N Y Y 70 OS (HR 3.579; 1.506 to 8.506)
luminal A
NA Done
OS (HR 3.232;1.839 to 5.678)
luminal B (high Ki67)




All 202/184/6581 Y Y Y 100 OS (HR 1.87;1.25 to 2.81) 1.Hormone receptor+/
HER2 +
NA Done
CSS (HR1.85;1.17 to 2.92) 2.Chemotherapy and
endocrine therapy
DFS (HR 1.59, 1.06 to 2.39)
1Hazard ratio (HR) for metformin (met) versus non-metformin (non-met) (reference): He et al., Peeters et al., Lega et al. HR for non-metformin versus metformin (reference): Bayraktar et al. Xiao et al., Present study
2Metformin versus non diabetes mellitus (DM) (reference) 3Non-metformin versus non diabetes mellitus (reference). OS, overall survival; CSS, cancer-specific survival; DMFS, distant metastasis-free survival;
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sponse rate than diabetic patients not receiving this drug
(odds ratio 2.95; 95 % CI 1.07 to 8.17; P = 0.04) [11]. Re-
cently, a phase III trial of adjuvant metformin has been
initiated in women with breast cancer (MCIC CTG
MA32) [9]. However, several years of follow-up are
needed to determine the survival benefits of metfor-
min. Moreover, a phase II clinical trial evaluating the
antitumor effect of neoadjuvant metformin in post-
menopausal women with ER-positive breast cancer
with letrozole plus metformin or placebo is ongoing
[10]. This trial will likely indicate the antitumor ef-
fects of metformin in breast cancer.
The present study had several limitations. First, the
small sample size limits our ability to make firm conclu-
sions. Second, a limitation of the present study is the
lack of information on the metformin dose. Patients
often receive more than one antidiabetic medication or
insulin and undergo changes in their pharmacotherapy
regimen over time. A recent population-based study
showed no significant association between cumulative
duration of past metformin use and improved survival
[14]. Moreover, because the present study focuses on
metformin as an antitumor drug that can reduce tumor
recurrence, the past history of metformin treatment be-
fore breast cancer diagnosis was not considered. Finally,
this study did not consider the severity or duration of
diabetes. The use of metformin in the diabetic cohort
could result in better glucose control and help maintain
adequate BMI. Diabetic patients who do not take
metformin have increased comorbidity compared with
patients who take metformin, indicating a possible
selection bias. Serial reduction of BMI could not be
evaluated in the present study. But this study com-
pared serum glucose on breast cancer surgery and the
hbA1C level, which stands for the severity of diabetes
for diabetic patients, but there were no significant
difference between the groups.
Both the tumor-suppressing activities of metformin
and the tumor-promoting effects of other diabetic condi-
tions may also contribute to the relative survival benefit
of metformin observed in our current study. Our present
findings support the hypothesis that metformin improves
the survival of breast cancer patients with concurrent
diabetes, particularly in cases with hormone-responsive
and HER2-positive tumors, receiving adjuvant systemic
therapy.
Conclusion
This study is the first report to show an association be-
tween metformin and long-term breast cancer survival ac-
cording to cancer subtype through the evaluation of
breast cancer characteristics and metformin treatment.
Moreover, our present findings can provide a backgroundfor future translational research and clinical work. We
await the results of ongoing randomized trials of metfor-
min as a treatment option for breast cancer patients.
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